Literature DB >> 24578331

Association of C4d deposition with clinical outcomes in IgA nephropathy.

Mario Espinosa1, Rosa Ortega, Marina Sánchez, Alfons Segarra, Maria Teresa Salcedo, Fayna González, Rafael Camacho, Miguel Angel Valdivia, Rocio Cabrera, Katia López, Fernando Pinedo, Eduardo Gutierrez, Alfonso Valera, Miryam Leon, Maria Angeles Cobo, Rosa Rodriguez, Jose Ballarín, Yolanda Arce, Beatriz García, María Dolores Muñoz, Manuel Praga.   

Abstract

BACKGROUND AND OBJECTIVES: Several studies have suggested that activation of the complement system is a contributing pathogenic mechanism in IgA nephropathy (IgAN). C4d staining is an inexpensive and easy-to-perform method for the analysis of renal biopsies. This study aimed to assess the clinical and prognostic implications of C4d staining in IgAN. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This retrospective cohort study included 283 patients with IgAN in 11 hospitals in Spain who underwent a renal biopsy between 1979 and 2010. The primary predictor was mesangial C4d staining. Secondary predictors included demographic, clinical, and laboratory characteristics, and Oxford pathologic classification criteria. The primary end point was the cumulative percentage of patients who developed ESRD, defined as onset of chronic dialysis or renal transplantation. C4d was analyzed by immunohistochemical staining using a polyclonal antibody. Kaplan-Meier and Cox proportional hazards analyses were performed to evaluate the effect of C4d staining on renal survival.
RESULTS: There were 109 patients (38.5%) and 174 patients (61.5%) who were classified as C4d positive and C4d negative, respectively. Renal survival at 20 years was 28% in C4d-positive patients versus 85% in C4d-negative patients (P<0.001). Independent risk factors associated with ESRD were as follows: proteinuria (hazard ratio [HR] per every 1 g/d increase. 1.16; 95% confidence interval [95% CI], 1.03 to 1.31; P=0.01), eGFR (HR per every 1 ml/min per 1.73 m(2) increase, 0.96; 95% CI, 0.94 to 0.97; P<0.001), T2 Oxford classification (tubular atrophy/interstitial fibrosis, >50%; HR, 4.42; 95% CI, 1.40 to 13.88; P=0.01), and C4d-positive staining (HR, 2.45; 95% CI, 1.30 to 4.64; P=0.01).
CONCLUSIONS: C4d-positive staining is an independent risk factor for the development of ESRD in IgAN. This finding is consistent with the possibility that complement activation is involved in the pathogenesis of this disease.

Entities:  

Keywords:  IgA nephropathy; complement; survival

Mesh:

Substances:

Year:  2014        PMID: 24578331      PMCID: PMC4011455          DOI: 10.2215/CJN.09710913

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  36 in total

Review 1.  Capillary C4d deposition as a marker of humoral immunity in renal allograft rejection.

Authors:  Bruno Watschinger; Manuel Pascual
Journal:  J Am Soc Nephrol       Date:  2002-09       Impact factor: 10.121

Review 2.  IgA nephropathy.

Authors:  James V Donadio; Joseph P Grande
Journal:  N Engl J Med       Date:  2002-09-05       Impact factor: 91.245

Review 3.  The interaction between complement component C4b-binding protein and the vitamin K-dependent protein S forms a link between blood coagulation and the complement system.

Authors:  M Hessing
Journal:  Biochem J       Date:  1991-08-01       Impact factor: 3.857

Review 4.  IgA nephropathy.

Authors:  Robert J Wyatt; Bruce A Julian
Journal:  N Engl J Med       Date:  2013-06-20       Impact factor: 91.245

5.  Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses.

Authors:  E Alamartine; J C Sabatier; C Guerin; J M Berliet; F Berthoux
Journal:  Am J Kidney Dis       Date:  1991-07       Impact factor: 8.860

6.  Predicting progression in IgA nephropathy.

Authors:  L P Bartosik; G Lajoie; L Sugar; D C Cattran
Journal:  Am J Kidney Dis       Date:  2001-10       Impact factor: 8.860

Review 7.  Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors.

Authors:  G D'Amico
Journal:  Am J Kidney Dis       Date:  2000-08       Impact factor: 8.860

8.  Prognostic indicators of IgA nephropathy in the Chinese--clinical and pathological perspectives.

Authors:  Philip Kam Tao Li; Kelvin Kai Leung Ho; Cheuk Chun Szeto; LyMee Yu; Fernand Mac-Moune Lai
Journal:  Nephrol Dial Transplant       Date:  2002-01       Impact factor: 5.992

9.  Polymeric IgA1 from patients with IgA nephropathy upregulates transforming growth factor-beta synthesis and signal transduction in human mesangial cells via the renin-angiotensin system.

Authors:  Kar Neng Lai; Sydney C W Tang; Jinn-Yuh Guh; Tsai-Der Chuang; Man Fai Lam; Loretta Y Y Chan; Anita W L Tsang; Joseph C K Leung
Journal:  J Am Soc Nephrol       Date:  2003-12       Impact factor: 10.121

10.  Classical pathway of complement activation in normal and diseased human glomeruli.

Authors:  J Zwirner; E Felber; V Herzog; G Riethmüller; H E Feucht
Journal:  Kidney Int       Date:  1989-12       Impact factor: 10.612

View more
  59 in total

1.  Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN.

Authors:  Sanjeev Sethi; Mark Haas; Glen S Markowitz; Vivette D D'Agati; Helmut G Rennke; J Charles Jennette; Ingeborg M Bajema; Charles E Alpers; Anthony Chang; Lynn D Cornell; Fernando G Cosio; Agnes B Fogo; Richard J Glassock; Sundaram Hariharan; Neeraja Kambham; Donna J Lager; Nelson Leung; Michael Mengel; Karl A Nath; Ian S Roberts; Brad H Rovin; Surya V Seshan; Richard J H Smith; Patrick D Walker; Christopher G Winearls; Gerald B Appel; Mariam P Alexander; Daniel C Cattran; Carmen Avila Casado; H Terence Cook; An S De Vriese; Jai Radhakrishnan; Lorraine C Racusen; Pierre Ronco; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2015-11-13       Impact factor: 10.121

Review 2.  Immunoglobulin A nephropathy: a pathophysiology view.

Authors:  Rafaela Cabral Gonçalves Fabiano; Sérgio Veloso Brant Pinheiro; Ana Cristina Simões E Silva
Journal:  Inflamm Res       Date:  2016-06-28       Impact factor: 4.575

3.  Combined C4d and CD3 immunostaining predicts immunoglobulin (Ig)A nephropathy progression.

Authors:  B Faria; C Henriques; A C Matos; M R Daha; M Pestana; M Seelen
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

4.  C4d Staining in the Diagnosis of C3 Glomerulopathy.

Authors:  H Terence Cook
Journal:  J Am Soc Nephrol       Date:  2015-05-19       Impact factor: 10.121

5.  Persistent Microscopic Hematuria as a Risk Factor for Progression of IgA Nephropathy: New Floodlight on a Nearly Forgotten Biomarker.

Authors:  Rosanna Coppo; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2017-07-24       Impact factor: 10.121

6.  C4d deposits in IgA nephropathy: where does complement activation come from?

Authors:  Rosanna Coppo
Journal:  Pediatr Nephrol       Date:  2017-02-14       Impact factor: 3.714

7.  C4d as a Diagnostic Tool in Proliferative GN.

Authors:  Sanjeev Sethi; Samih H Nasr; An S De Vriese; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2015-05-19       Impact factor: 10.121

8.  Mesangial C4d Deposits in Early IgA Nephropathy.

Authors:  Alfons Segarra; Katheryne Romero; Irene Agraz; Natalia Ramos; Alvaro Madrid; Clara Carnicer; Elias Jatem; Ramón Vilalta; Luis Enrique Lara; Elena Ostos; Naiara Valtierra; Juliana Jaramillo; Karla V Arredondo; Gema Ariceta; Cristina Martinez
Journal:  Clin J Am Soc Nephrol       Date:  2017-11-16       Impact factor: 8.237

Review 9.  Biomarkers and targeted new therapies for IgA nephropathy.

Authors:  Rosanna Coppo
Journal:  Pediatr Nephrol       Date:  2016-06-20       Impact factor: 3.714

10.  Deletion Variants of CFHR1 and CFHR3 Associate with Mesangial Immune Deposits but Not with Progression of IgA Nephropathy.

Authors:  Perrine Jullien; Blandine Laurent; Guillaume Claisse; Ingrid Masson; Miriana Dinic; Damien Thibaudin; Francois Berthoux; Eric Alamartine; Christophe Mariat; Nicolas Maillard
Journal:  J Am Soc Nephrol       Date:  2017-11-07       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.